OXPHOS-targeting drugs in oncology: new perspectives.
Kalyanaraman B, Cheng G, Hardy M, You M.
Expert Opin Ther Targets. 2023 Jul-Dec;27(10):939-952. doi: 10.1080/14728222.2023.2261631. Epub 2023 Oct 30.
Targeted Drug Delivery: Trends and Perspectives.
Ashique S, Sandhu NK, Chawla V, Chawla PA.
Curr Drug Deliv. 2021;18(10):1435-1455. doi: 10.2174/1567201818666210609161301.
Precision medicine in acute lymphoblastic leukemia.
Pui CH.
Front Med. 2020 Dec;14(6):689-700. doi: 10.1007/s11684-020-0759-8. Epub 2020 Oct 19.
Reengineering Endogenous Targeting Lipid Nanoparticles (ENDO) for Systemic Delivery of mRNA to Pancreas.
Isaac I, Patel L, Tran N, Singam A, Yun D, Guha P, Park S, Bhattacharya C.
Adv Mater. 2025 Oct;37(40):e2507657. doi: 10.1002/adma.202507657. Epub 2025 Jun 12.
[Dose escalation strategies of molecular target drugs].
Tahara M, Sasaki Y.
Gan To Kagaku Ryoho. 2000 Oct;27(11):1759-63.
Zinc cyclic di-AMP nanoparticles target and suppress tumours via endothelial STING activation and tumour-associated macrophage reinvigoration.
Yang K, Han W, Jiang X, Piffko A, Bugno J, Han C, Li S, Liang H, Xu Z, Zheng W, Wang L, Wang J, Huang X, Ting JPY, Fu YX, Lin W, Weichselbaum RR.
Nat Nanotechnol. 2022 Dec;17(12):1322-1331. doi: 10.1038/s41565-022-01225-x. Epub 2022 Oct 27.
Hybrid proton-photon inverse optimization with uniformity-regularized proton and photon target dose.
Gao H.
Phys Med Biol. 2019 May 8;64(10):105003. doi: 10.1088/1361-6560/ab18c7.
Expanding RNAi to Kidneys, Lungs, and Spleen via Selective ORgan Targeting (SORT) siRNA Lipid Nanoparticles.
Vaidya A, Moore S, Chatterjee S, Guerrero E, Kim M, Farbiak L, Dilliard SA, Siegwart DJ.
Adv Mater. 2024 Aug;36(35):e2313791. doi: 10.1002/adma.202313791. Epub 2024 Jul 8.
The physiological limits of bispecific monoclonal antibody tissue targeting specificity.
Sepp A, Stader F, Derbalah A, Liu C, Zyla A, Gardner I, Jamei M.
MAbs. 2025 Dec;17(1):2492236. doi: 10.1080/19420862.2025.2492236. Epub 2025 Apr 13.
Heterogeneous Off-Target Effects of Ultra-Low Dose Dimethyl Sulfoxide (DMSO) on Targetable Signaling Events in Lung Cancer In Vitro Models.
Baldelli E, Subramanian M, Alsubaie AM, Oldaker G, Emelianenko M, El Gazzah E, Baglivo S, Hodge KA, Bianconi F, Ludovini V, Crino' L, Petricoin EF, Pierobon M.
Int J Mol Sci. 2021 Mar 10;22(6):2819. doi: 10.3390/ijms22062819.
